(Q53216225)

12 May 2018

title

Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. (English)

1 reference

12 May 2018

multicenter clinical trial

1 reference

1 reference

3

Frank L Greenway

1 reference

12 May 2018

author name string

Steven R Smith

1

1 reference

12 May 2018

Kaj S Stenlof

2

1 reference

12 May 2018

John McHutchison

4

1 reference

12 May 2018

Susan M Schwartz

5

1 reference

12 May 2018

Vidhu B Dev

6

1 reference

12 May 2018

Evan S Berk

7

1 reference

12 May 2018

Roxanne Kapikian

8

1 reference

12 May 2018

publication date

30 June 2011

1 reference

12 May 2018

published in

Obesity

1 reference

12 May 2018

volume

19

1 reference

12 May 2018

issue

9

1 reference

12 May 2018

page(s)

1796-1803

1 reference

12 May 2018

Abdominal obesity and metabolic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Influence of body fat content and distribution on variation in metabolic risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Role of body fat distribution and the metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Visceral fat and liver fat are independent predictors of metabolic risk factors in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Validation of a quantitative magnetic resonance method for measuring human body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic resonance images

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Methods for assessing intrahepatic fat content and steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Identification of individuals with insulin resistance using routine clinical measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Visceral Fat Is an Independent Predictor of All-cause Mortality in Men*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Effect of obesity on bioelectrical impedance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Visceral adipose tissue: a critical review of intervention strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

Pragmatic study of orlistat 60 mg on abdominal obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.143

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2011.143

1 reference

12 May 2018

1 reference

12 May 2018